Apixaban prophylactic anticoagulation in patients with nephrotic syndrome.
Background: Nephrotic syndrome (NS) is associated with an increased risk of thromboembolic events (TE), due to hemostatic derangements. The use of direct oral anticoagulants (DOAC) in the prevention of TE hasn’t been studied intensively in patients suffering from NS. Methods: Retrospective analysis of consecutive incident patients with NS due to glomerular disease, receiving apixaban for thrombophylaxis. It is an uncontrolled, single center study. Results: We identified 27 patients treated with apixaban for the prevention of TE, in the context of NS. During follow-up apixaban Cmin and Cmax levels were measured. The mean duration of the anticoagulant treatment was 153 days (± 132). Patients were followed for a mean of 14.7 months (± 8.4) since the introduction of apixaban. Three patients had a TE at the time of NS diagnosis. Two patients had pulmonary embolism (PE) and one patient presented a stroke in lupus membranous nephropathy context. One patient developed PE approximately 2 months after introduction of apixaban treatment. No minor nor major bleeding events were noticed. Conclusion: The present study shows that patients, suffering from severe NS under anticoagulant therapy with apixaban had reduced risk of venous and arterial TE compared to patients previously described in the literature, without increased risk of bleeding.
- Weitere Titel
-
Apixaban in nephrotic syndrome
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Apixaban prophylactic anticoagulation in patients with nephrotic syndrome. ; day:08 ; month:08 ; year:2022
TH open ; (08.08.2022)
- Beteiligte Personen und Organisationen
-
VAN MEERHAEGHE, Tess
Cez, Alexandre
Dahan, Karine
Esteve, Emmanuel
Elalamy, Ismail
Ponlot, Eleonore
Boffa, Jean Jacques
- DOI
-
10.1055/a-1920-6224
- URN
-
urn:nbn:de:101:1-2022092411235472348123
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- VAN MEERHAEGHE, Tess
- Cez, Alexandre
- Dahan, Karine
- Esteve, Emmanuel
- Elalamy, Ismail
- Ponlot, Eleonore
- Boffa, Jean Jacques
Ähnliche Objekte (12)
Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications
Urokinase prophylactic anticoagulation in children with nephrotic syndrome: a multicenter retrospective cohort study
Longitudinal Analysis of Prophylactic Anticoagulation in Primary Nephrotic Syndrome: Low Incidence of Thromboembolic Complications
Role of anticoagulation with apixaban in left-sided atrial tachycardias
Congenital nephrotic syndrome
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Diabetes and nephrotic syndrome: Answers
Familial forms of nephrotic syndrome
Diabetes and nephrotic syndrome: Questions
Cyclosporin A (Sandimmun) in nephrotic syndrome
Rituximab for nephrotic syndrome in children
An unusual case of nephrotic syndrome
Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications
Urokinase prophylactic anticoagulation in children with nephrotic syndrome: a multicenter retrospective cohort study
Longitudinal Analysis of Prophylactic Anticoagulation in Primary Nephrotic Syndrome: Low Incidence of Thromboembolic Complications
Role of anticoagulation with apixaban in left-sided atrial tachycardias
Congenital nephrotic syndrome
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Diabetes and nephrotic syndrome: Answers
Familial forms of nephrotic syndrome
Diabetes and nephrotic syndrome: Questions
Cyclosporin A (Sandimmun) in nephrotic syndrome
Rituximab for nephrotic syndrome in children
An unusual case of nephrotic syndrome
Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications
Urokinase prophylactic anticoagulation in children with nephrotic syndrome: a multicenter retrospective cohort study
Longitudinal Analysis of Prophylactic Anticoagulation in Primary Nephrotic Syndrome: Low Incidence of Thromboembolic Complications
Role of anticoagulation with apixaban in left-sided atrial tachycardias
Congenital nephrotic syndrome
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Diabetes and nephrotic syndrome: Answers
Familial forms of nephrotic syndrome
Diabetes and nephrotic syndrome: Questions
Cyclosporin A (Sandimmun) in nephrotic syndrome
Rituximab for nephrotic syndrome in children